Urolithin A is a gut-derived metabolite that has moved from niche biochemistry journals into mainstream supplement conversations. Its popularity is largely due to its role in mitophagy, the selective recycling of damaged mitochondria. The growing body of human clinical data positions Urolithin A benefits for mitochondrial health at a unique intersection.
It connects cellular energy renewal, improved muscle function, and a biological rationale for healthy aging. These effects often begin with the consumption of precursor-rich foods like walnuts and various berries. Many of these insights stem from the study of Mitopure, a standardized form of the compound used in research to support muscle strength.
What makes Urolithin A distinct from other longevity supplements is that its mechanism, activating mitophagy through the PINK1/Parkin pathway, has been validated in human tissue, not just cell culture or animal models. That does not mean every claim circulating online is warranted. The gap between biological plausibility and confirmed clinical benefit is real, and navigating it matters whether you are a consumer evaluating a purchase or a brand deciding whether to formulate with this ingredient.
This guide walks through the science in layers: what is urolithin a, how your body encounters it, and the mechanism by which it acts. We will also explore how the gut microbiome facilitates this process. We will also explore what human trials currently support, what remains speculative, and how to think about Urolithin A dosage, safety, and ingredient quality. If you are sourcing bulk Urolithin A powder for product development or simply deciding whether a capsule belongs in your daily routine, the goal is to give you a clear, evidence-grounded framework. For B2B buyers evaluating supply partners, Provita Biotech offers high-purity Urolithin A raw material with full documentation, OEM support, and international logistics from facilities in Shanghai, Melbourne, California, and Rotterdam.
Urolithin A Benefits and Scientific Identity
To understand what is urolithin a, one must look at how the body processes specific plant nutrients. It is a natural compound that bridges the gap between nutrition and cellular efficiency. As a nutritional supplement, it offers a standardized way to ensure the body receives the metabolite even if internal production is low. This ensures users receive the expected Urolithin A benefits regardless of their gut bacteria. Its scientific identity and classification as a postbiotic metabolite shape how it performs. These factors are critical for effective energy production and cellular health.
Scientific Identity And Basic Properties
Urolithin A belongs to a family of dibenzopyranones. Often referred to as UA, this natural compound is characterized by poor Urolithin A water solubility. This physical property directly limits its oral bioavailability in simple powder form.
Urolithin A stability is reasonable under dry storage conditions, but the compound is sensitive to light and oxidative degradation over time. Particle size matters commercially: micronized Urolithin A dissolves more readily in the gastrointestinal tract, and suppliers offering Urolithin A 98% or Urolithin A 99% purity grades typically specify particle-size distribution on their certificates of analysis.
For formulators, these physical properties dictate whether a straightforward powder blend is sufficient or whether bioavailability enhancement technologies like microencapsulation or liposomal delivery are necessary.
How It Differs From Urolithin B, Isourolithin A, And Urolithin A Diacetate
Not all urolithins are equivalent. Urolithin B has only one hydroxyl group and shows weaker mitophagy-activating potential. Isourolithin A is a positional isomer that appears in lower quantities in most human subjects.
Urolithin A diacetate is a synthetic acetylated derivative sometimes encountered in raw material sourcing. It is not the same molecule as purified Urolithin A, though it can be hydrolyzed back to the parent compound in the body. From a regulatory and labeling standpoint, the distinction matters: clinical trials supporting Urolithin A health benefits used purified Urolithin A, not the diacetate form. If you are evaluating a supplier’s certificate of analysis, confirm that the assay specifically identifies Urolithin A via HPLC, not a mixture of urolithin species or a prodrug analog.
Why Urolithin A Is Positioned As A Postbiotic Metabolite
The term “postbiotic” refers to bioactive compounds produced by microbial metabolism, distinct from the live organisms (probiotics) or their food sources (prebiotics). Urolithin A fits this definition precisely: it is not present in the food you eat, but is generated by your intestinal microbiota after you consume ellagitannin-rich foods.
This classification carries practical weight. Because Urolithin A is a microbial metabolite rather than a direct plant extract, production at commercial scale typically relies on chemical synthesis or fermentation-based biosynthesis rather than extraction from pomegranates or walnuts. The Urolithin A manufacturing process, whether synthetic or fermentation-derived, determines purity profile, residual solvent content, and regulatory classification.
For supplement brands, understanding the postbiotic framing helps position Urolithin A accurately in marketing materials and supports defensible structure-function claims.
From Food Precursors To Human Exposure
The route from dietary polyphenol to circulating Urolithin A involves microbial conversion, individual variability in gut flora, and pharmacokinetic realities that explain why food alone rarely delivers consistent exposure.
Ellagitannins, Ellagic Acid, And Microbial Conversion
Ellagitannins are polyphenols found in pomegranate, walnuts, and various berries. Consuming a variety of berries allows your gut microbiome to begin the conversion process. The natural fiber and nutrients in berries also support a healthy gut environment.
In the stomach, ellagitannins hydrolyze into ellagic acid. Ellagic acid itself is poorly absorbed, so most of it reaches the colon intact. There, gut bacteria perform a stepwise transformation into the final metabolite.
There, specific gut bacteria perform a stepwise transformation. They progressively remove hydroxyl groups and open lactone rings, converting ellagic acid first into intermediate urolithins and ultimately into Urolithin A. This UA conversion pathway means the compound is never directly present in the foods you eat. Pomegranate ellagitannins are the most studied precursors. However, the efficiency of conversion depends entirely on the bacterial species present in your gut microbiome.
Urolithin Metabotypes And Why Responses Differ
Researchers have classified human populations into three Urolithin metabotypes based on the urolithin profile detected in urine after consuming ellagitannin-rich foods.
- Urolithin metabotype A (UM-A): Produces predominantly Urolithin A. Roughly 40 to 60 percent of Western populations fall into this group.
- Urolithin metabotype B (UM-B): Produces a mixture of Urolithin A, Urolithin B, and isourolithin A. This group represents approximately 25 to 40 percent of the population.
- Urolithin metabotype 0 (UM-0): Produces no detectable urolithins at all. Estimates range from 5 to 15 percent of individuals.
This variability is one of the strongest arguments for direct Urolithin A supplementation rather than relying on pomegranate juice or walnut intake. If your gut microbiome lacks the right bacterial strains, no amount of polyphenol-rich foods will generate meaningful Urolithin A levels in your bloodstream.
Foods That Supply Precursors Rather Than Standardized Urolithin A
Pomegranate juice, pomegranate extract, walnuts, raspberries, blackberries, and strawberries are all legitimate natural sources of Urolithin A precursors. While strawberries contain these compounds, the amount can vary significantly between different harvests. Consuming mixed berries can provide a broad spectrum of protective polyphenols.
Pomegranate benefits for cardiovascular markers in some studies may partly reflect urolithin production in UM-A individuals. Isolating that contribution from the fruit’s other bioactives remains a challenge for researchers. Many individuals include berries in their breakfast to boost their intake of these vital precursors.
The practical limitation is dose consistency. A glass of pomegranate juice delivers a variable amount of ellagitannins depending on cultivar, ripeness, and processing. Even in a UM-A individual, the resulting plasma Urolithin A concentration is typically lower and more variable than what clinical trials achieved with 500 mg or 1,000 mg of purified Urolithin A.
For brands positioning products as “Urolithin A from pomegranate,” it is worth noting that pomegranate extract and Urolithin A are not interchangeable claims. Regulatory frameworks in both the US and EU distinguish between the two. A pomegranate extract delivers ellagitannins; a Urolithin A supplement delivers the end metabolite directly.
How Urolithin A Works In The Body
Urolithin A’s mechanism of action centers on selective clearance of damaged mitochondria, with downstream effects on energy metabolism and cellular renewal. The way it is absorbed and circulates in your body also shapes what formulators can realistically expect from different delivery formats.
Mitophagy And Mitochondrial Quality Control
Mitophagy is the targeted form of autophagy that removes dysfunctional mitochondria. This process is essential for maintaining mitochondrial health. Urolithin A activates this pathway to prevent damaged organelles from impairing energy production. This activation occurs through the PINK1/Parkin pathway. By supporting mitochondrial function, the cell can focus on generating new, healthy mitochondria for better cellular energy.
By clearing damaged mitochondria, the cell shifts resources toward mitochondrial biogenesis, the generation of new, functional organelles. This mitochondrial renewal cycle is central to its positioning as a mitophagy activator. Supporting these processes is essential for cellular health and maintaining energy balance.
In preclinical models, Urolithin A–treated cells show measurably improved mitochondrial membrane potential and oxygen consumption rates. The distinction from broad autophagy inducers like spermidine is specificity. While compounds like NAD+ boosters or NR focus on fueling mitochondria, Urolithin A preferentially targets mitochondrial dysfunction.
Cellular Energy Metabolism, ATP, And Fatty Acid Oxidation
When mitochondrial quality control operates efficiently, the downstream effect is improved ATP production. Skeletal muscle, cardiac tissue, and neurons are especially dependent on mitochondrial output, which is why age-related mitochondrial dysfunction correlates with muscle fatigue, reduced exercise capacity, and cognitive decline.
Preclinical evidence suggests Urolithin A supports fatty acid oxidation within mitochondria, potentially improving the cell’s ability to use lipids as fuel. In the context of sports nutrition and active aging, this is relevant because endurance-type exercise relies heavily on mitochondrial fat metabolism.
It is important to note that increased ATP production has been measured as a biomarker in human studies (specifically maximal ATP production in hand skeletal muscle via magnetic resonance spectroscopy), but the clinical significance of modest changes in this marker is still being defined.
Absorption, Circulating Metabolites, And Formulation Constraints
After oral ingestion, Urolithin A absorption occurs primarily in the small intestine. In first-in-human pharmacokinetic data, peak plasma concentrations (Tmax) appeared approximately six hours post-dose, with an elimination half-life of roughly 24 hours, supporting once-daily dosing.
Circulating forms are predominantly phase II conjugates: Urolithin A glucuronide and Urolithin A sulfate. These conjugated metabolites are the dominant species detected in plasma, and their biological activity, while assumed to be meaningful, is less well characterized than that of the parent aglycone.
Poor Urolithin A solubility limits absorption from simple powder-filled capsules. This is where formulation technology becomes commercially decisive. Approaches like liposomal encapsulation, microencapsulation, and particle-size reduction (micronized Urolithin A) aim to improve Urolithin A bioavailability by increasing surface area or protecting the compound through gastric transit. Suppliers with in-house capabilities in these areas, such as Provita Biotech with its liposomal delivery and microencapsulation platforms, offer B2B partners options beyond commodity powder.
What Human Studies Currently Support
The human evidence base for Urolithin A is growing but still limited in scope. While earlier animal studies provided a strong foundation, recent randomized, placebo-controlled trials involving middle-aged adults have been published. You can find many of these clinical summaries on NCBI, PubMed, and other scientific databases.
Mitophagy, Mitochondrial Biomarkers, And Healthy Aging Positioning
The first-in-human trial established that single and repeated oral doses of Urolithin A were safe. These trials produced dose-dependent plasma concentrations in healthy elderly subjects over 28 days. If you are checking your browser for the latest clinical data, you will see that these results laid the groundwork for larger investigations into muscle and metabolic outcomes. Importantly, this trial also reported changes in mitochondrial biomarkers: participants showed favorable shifts in plasma acylcarnitines and ceramides, lipid species associated with mitochondrial and metabolic health.
These biomarker changes provide a mechanistic bridge between the preclinical mitophagy data and potential real-world outcomes. They do not, on their own, prove that supplementation extends lifespan or reverses biological aging. The positioning of Urolithin A as a geroprotective compound rests on the plausibility of improved mitochondrial quality control as a driver of healthspan, a framing that is biologically reasonable but not yet confirmed by long-duration human outcome trials.
Muscle Endurance, Strength, Physical Function, And Exercise Capacity
The most clinically tangible Urolithin A health benefits reported so far involve skeletal muscle and the mitigation of age-related muscle decline. Research suggests that optimizing muscle function is key to preserving mobility as we age. In a four-month randomized controlled trial with older adults, those taking Urolithin A showed improvements in muscle endurance. Specifically, participants saw gains in hamstring and knee extensor fatigue resistance compared to placebo.
Key details worth noting:
- Muscle endurance improved significantly in the supplemented group.
- Hamstring muscle strength increased by approximately 12% at 500 mg daily.
- Six-minute walk distance showed a trend toward improvement but did not reach statistical significance versus placebo.
- Maximal ATP production in hand skeletal muscle trended upward but, again, was not significant versus placebo in the primary analysis.
A shorter-term trial in middle-aged active adults reported reductions in plasma biomarkers of muscle damage. This was accompanied by improvements in markers of aerobic endurance, signaling better exercise performance. These benefits for exercise performance are a key focus for athletes using UA. These findings make it an interesting addition to the landscape of dietary supplements for athletes. These results are relevant for sports nutrition applications and for individuals maintaining an active lifestyle into middle age.
The collective picture shows that Urolithin A benefits for muscle health are supported by positive signals. These outcomes suggest a measurable impact on muscle function and overall exercise performance. Researchers often use Mitopure to demonstrate these effects on muscle strength. These findings are relevant for individuals seeking to maintain exercise performance while supporting long-term mitochondrial health.
Immune, Inflammatory, Metabolic, And Recovery Signals
A recent human trial specifically examined the immune health effects of Urolithin A in older adults. Supplementation was associated with improvements in circulating immune cell composition, including favorable shifts in T-cell subsets and natural killer cell profiles. T-cell metabolism appeared to improve, consistent with the idea that immune cells, which are highly mitochondria-dependent, benefit from enhanced mitophagy.
Inflammatory biomarkers, including C-reactive protein (CRP) and IL-1β, showed modest reductions in some analyses. This reflects the anti-inflammatory properties often associated with mitochondrial optimization. It suggests a potential role in managing inflammaging, the chronic low-grade inflammation associated with aging. The reduction in oxidative stress markers aligns with the compound’s antioxidant activity observed in preclinical work.
Metabolic signals, including changes in ceramides, acylcarnitines, and markers associated with lipid metabolism and insulin sensitivity, have been reported as secondary outcomes. These are hypothesis-generating rather than confirmatory: they suggest directions for future research on metabolic health rather than establishing clinical benefits.
For post-exercise recovery, the reduction in muscle damage biomarkers observed in the shorter-term active-adult trial is of practical interest to athletes and active aging populations, though replication in larger cohorts is needed.
Potential Applications That Remain Preliminary
Several areas of Urolithin A research generate significant consumer interest but lack direct human clinical evidence. These applications are biologically plausible given the compound’s mitochondrial mechanism, yet they should be clearly distinguished from the more substantiated muscle and aging data.
Brain, Cognitive, And Neuroprotective Research
Neurons are among the most mitochondria-dense cells in your body, which makes them theoretically responsive to a mitophagy activator. Preclinical models have shown that Urolithin A reduces neuroinflammation. It also improves mitochondrial function in brain tissue. These animal studies suggest potential anti-aging benefits for the central nervous system.
No controlled human trial has yet measured cognitive outcomes with Urolithin A supplementation. Computational analyses have identified multi-target interactions that could modulate neurodegeneration-related pathways, but these remain in silico predictions. Framing Urolithin A as a neuroprotection supplement would be premature based on current evidence.
Cardiovascular And Vascular Questions
Cardiovascular health is another area where mitochondrial dysfunction contributes to disease progression. Preclinical data suggest that Urolithin A may improve endothelial function and reduce vascular inflammation. Some of the pomegranate benefits historically attributed to juice consumption could theoretically involve urolithin production in the gut, though isolating that mechanism from the broader polyphenol profile of pomegranate extract is difficult.
No human trials have tested cardiovascular endpoints as primary outcomes. The metabolic biomarker shifts (ceramides, lipid profiles) observed in existing trials provide indirect evidence of potential vascular relevance, but they fall short of establishing heart health claims.
Skin And Topical Use Considerations
Interest in Urolithin A for skin health stems from its role in mitochondrial renewal and its observed antioxidant activity in preclinical skin models. Studies in cell culture suggest it may counteract photoaging, support collagen synthesis pathways, and reduce UV-induced oxidative damage.
Topical formulations are being explored commercially, but absorption through the skin barrier presents bioavailability challenges distinct from those of oral supplementation. No published human skin trials with clinically relevant endpoints (wrinkle depth, elasticity, pigmentation) were available at the time of this writing. Brands interested in skin-aging applications should treat this as an emerging opportunity requiring proprietary efficacy testing.
Choosing Supplements, Evaluating Dosage, And Assessing Safety
The decision between food-based intake and direct Urolithin A supplementation, the doses supported by clinical data, and the quality benchmarks that matter for both consumers and commercial buyers all deserve careful consideration.
Food Versus Direct Supplementation
Eating pomegranates, walnuts, raspberries, and other polyphenol-rich foods provides genuine nutritional value. These foods deliver ellagitannin precursors rather than standardized Urolithin A. While berries are a healthy dietary choice, they may not be enough for everyone.
An estimated 5 to 15 percent of the population belongs to Urolithin metabotype 0 and produces no urolithins. Even UM-A individuals show variable conversion efficiency. Therefore, food-based intake, such as eating berries daily, cannot guarantee meaningful plasma Urolithin A concentrations.
Direct supplementation with purified UA bypasses the gut microbiome conversion step entirely. This natural compound allows for consistent levels regardless of internal bacteria. Researchers used a standardized UA supplement rather than pomegranate extract to ensure consistent dosing and improve exercise performance.
Study Dosages, Timing, And Expectation Setting
Human clinical trials have tested daily doses of 250 mg, 500 mg, and 1,000 mg of Urolithin A, with study durations ranging from 28 days to four months.
| Dose | Duration | Key Observations |
|---|---|---|
| 250 mg/day | 28 days | Safe; dose-dependent plasma levels; biomarker shifts |
| 500 mg/day | 4 months | Improved muscle endurance; ~12% hamstring strength gain |
| 1,000 mg/day | 4 weeks–4 months | Consistent biomarker improvements; muscle damage reduction; endurance signals |
Peak plasma concentration occurs roughly six hours after ingestion, and the approximately 24-hour half-life supports once-daily dosing. Most commercial Urolithin A supplement products recommend taking the dose with food, though specific timing (morning versus evening) has not been formally optimized in trials.
Set expectations realistically. Published data suggest measurable benefits in muscle endurance and mitochondrial biomarkers over weeks to months. Claims of rapid energy boosts within days or dramatic anti-aging transformations are not supported by the existing evidence base.
Bulk Powder Quality, Purity, And Commercial Considerations
For B2B buyers, ingredient quality is the decisive variable. Not all Urolithin A powder on the market meets the same standards, and the gap between Urolithin A 98% and lower-purity material can affect both efficacy and regulatory compliance.
When evaluating a bulk Urolithin A supplier, request and verify:
- HPLC assay and chromatogram confirming identity as Urolithin A (not diacetate or mixed urolithins)
- Certificate of Analysis (COA) with purity, residual solvents, heavy metals, and microbial limits
- Third-party testing from an independent laboratory
- Regulatory documentation, including GRAS status (FDA GRAS Notice 791 covers specific Urolithin A preparations) and, for EU markets, Novel Food authorization status
Urolithin A stability under various storage conditions and its Urolithin A particle size distribution both influence shelf life and bioavailability in finished products. Suppliers offering micronized Urolithin A or advanced delivery formats (liposomal, microencapsulated) can help brands differentiate in a competitive market. Provita Biotech, for instance, supports OEM and private label customers with formulation development, Urolithin A bioavailability enhancement through its liposomal and microencapsulation platforms, and international certifications including ISO 9001, ISO 22000, GMP, HACCP, Halal, and Kosher.
Safety in published trials has been reassuring, with no serious adverse events reported. However, understanding potential side effects is important for consumers. Some mild side effects have been noted occasionally at higher doses. These may include gastrointestinal issues such as bloating or diarrhea. Long-term safety data beyond four months remain limited at this time. Pregnant or breastfeeding individuals should avoid supplementation for now. Those on medication should consult a healthcare professional before starting any new dietary supplements.
References
- Ryu, D., Mouchiroud, L., Andreux, P. A., Katsyuba, E., Moullan, N., Nicolet-dit-Félix, A. A., Williams, E. G., Jha, P., Lo Sasso, G., Huzard, D., Aebischer, P., Sandi, C., Rinsch, C., & Auwerx, J. (2016). Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine, 22(8), 879–888. https://doi.org/10.1038/nm.4132
- Andreux, P. A., Blanco-Bose, W., Ryu, D., Burdet, F., Ibberson, M., Aebischer, P., Auwerx, J., Singh, A., & Rinsch, C. (2019). The mitophagy activator Urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism, 1(6), 595–603. https://doi.org/10.1038/s42255-019-0073-4
- Liu, S., D’Amico, D., Shankland, E., Bhayana, S., Garcia, J. M., Aebischer, P., Rinsch, C., Singh, A., & Marcinek, D. J. (2022). Effect of Urolithin A supplementation on muscle endurance and mitochondrial health in older adults: A randomized clinical trial. JAMA Network Open, 5(1), e2144279. https://doi.org/10.1001/jamanetworkopen.2021.44279
- Singh, A., D’Amico, D., Andreux, P. A., Fouassier, A. M., Blanco-Bose, W., Evans, M., Aebischer, P., Auwerx, J., & Rinsch, C. (2022). Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine, 3(5), 100633. https://doi.org/10.1016/j.xcrm.2022.100633
- Cortés-Martín, A., Iglesias-Aguirre, C. E., Marín, A., Romo-Vaquero, M., Vallejo, F., Espín, J. C., & Selma, M. V. (2024). Urolithin A production drives the effects of pomegranate on the gut microbial metabolism of bile acids and cholesterol in mild dyslipidaemic overweight and obese individuals. Food & Function, 15, 2422–2432. https://doi.org/10.1039/D3FO05014A
- Kuerec, A. H., Lim, X. K., Khoo, A. L. Y., Sandalova, E., Guan, L., Feng, L., & Maier, A. B. (2024). Targeting aging with Urolithin A in humans: A systematic review. Ageing Research Reviews, 100, 102406. https://doi.org/10.1016/j.arr.2024.102406
- Denk, D., Singh, A., Kasler, H. G., D’Amico, D., Rey, J., Alcober-Boquet, L., Gorol, J. M., Steup, C., Tiwari, R., Kwok, R., Argüello, R. J., Faitg, J., Sprinzl, K., Zeuzem, S., Nekljudova, V., Loibl, S., Verdin, E., Rinsch, C., & Greten, F. R. (2025). Effect of the mitophagy inducer Urolithin A on age-related immune decline: A randomized, placebo-controlled trial. Nature Aging, 5(11), 2309–2322. https://doi.org/10.1038/s43587-025-00996-x
- Monsalve Acevedo, A., Sanctuary, C., Aitken, R. J., Wilkins, A., Harrison, N., & Naughton, M. (2025). Effects of Urolithin A supplementation on performance and antioxidant status in academy soccer players during preseason: A pilot randomized controlled trial. Frontiers in Nutrition, 12, 1674446. https://doi.org/10.3389/fnut.2025.1674446
